# Shanghai Ark Biopharmaceutical Co., Ltd. trials: 20 (2026)

ClinicalTrials.gov lists 20 trials with Shanghai Ark Biopharmaceutical Co., Ltd. as lead sponsor, 2 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Shanghai Ark Biopharmaceutical Co., Ltd.: 20 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/shanghai-ark-biopharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 22, 2026 | NCT07719023 | A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 263 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719023) |
| June 22, 2026 | NCT07658534 | A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection. | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 2/3 | Recruiting | Respiratory Syncytial Virus Infections | 290 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658534) |
| February 25, 2026 | NCT07432698 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AK0406 Injection in Healthy Adult Participants | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 1 | Active not recruiting | Healthy Participants | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07432698) |
| May 30, 2025 | NCT06996704 | A Clinical Study of AK0610 | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Volunteer Study | 147 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06996704) |
| April 24, 2025 | NCT06942299 | A Study of AK0529 in Adults Patients Hospitalized With RSV Infection | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 2 | Completed | Respiratory Syncytial Virus Infections | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06942299) |
| January 15, 2025 | NCT06775405 | A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 3 | Completed | Respiratory Synctial Virus Infections | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06775405) |
| September 19, 2024 | NCT06591845 | Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Volunteers | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06591845) |
| April 11, 2024 | NCT06359899 | A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 3 | Completed | ADHD | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06359899) |
| June 28, 2022 | NCT05434897 | A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 1/2 | Completed | Hypertrophic Scar | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05434897) |
| June 21, 2022 | NCT05424887 | A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 2 | Unknown | Idiopathic Pulmonary Fibrosis | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05424887) |
| June 14, 2021 | NCT04926116 | A Study of AK3280 in Chinese Healthy Volunteers | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04926116) |
| March 9, 2021 | NCT04788017 | A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Subjects | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04788017) |
| January 18, 2020 | NCT04231968 | A Study of AK0529 in Chinese Infants Hospitalized With RSV | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 3 | Completed | Respiratory Syncytial Virus Infections | 311 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04231968) |
| June 19, 2019 | NCT03990688 | A Study to Assess the Effect of AK3280 on Renal Function in Healthy Subjects | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03990688) |
| October 9, 2018 | NCT03699202 | Anti-RSV Study in Chinese Patients (ASCENT) | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 2 | Terminated | Respiratory Syncytial Virus Infections | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03699202) |
| January 17, 2018 | NCT03400995 | A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529 | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03400995) |
| October 26, 2017 | NCT03322800 | A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy Volunteers | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03322800) |
| January 13, 2016 | NCT02654171 | Viral Inhibition in Children for Treatment of RSV | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 2 | Completed | RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02654171) |
| June 2, 2015 | NCT02460016 | A Study of AK0529 in Infants Hospitalized With RSV | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 1 | Terminated | Respiratory Syncytial Virus Infections | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02460016) |
| November 21, 2014 | NCT02297594 | Safety, Tolerability and PK Study of AK0529 in Healthy Human | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 1 | Completed | Respiratory Syncytial Virus Infections | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02297594) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 14 |
| Terminated | 2 |
| Active not recruiting | 1 |
| Unknown | 1 |
| Recruiting | 1 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Respiratory Syncytial Virus Infections | 7 |
| Idiopathic Pulmonary Fibrosis | 2 |
| Cicatrix, Hypertrophic | 1 |
| Heart Diseases | 1 |
| Attention Deficit Disorder with Hyperactivity | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [African restaurants in the United States](https://specstream.ai/data/businesses/african-restaurants/united-states)
- [Mortgage lenders in the United States](https://specstream.ai/data/businesses/mortgage-lenders/united-states)
- [Contract law firms in the United States](https://specstream.ai/data/businesses/contract-law-firms/united-states)
- [Spices wholesalers in the United States](https://specstream.ai/data/businesses/spices-wholesalers/united-states)
- [Hospitals in the United States](https://specstream.ai/data/businesses/hospitals/united-states)
- [B2B oil and gas companies in the United States](https://specstream.ai/data/businesses/b2b-oil-and-gas-companies/united-states)
